Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen : Jan 26, 2007

Premium
Qiagen this week launched a rat druggable genome siRNA set V1.0, which has been designed to enable researchers to knock down around 6,000 rat genes that correspond to human genes of potential therapeutic value.
 
The company designed the siRNAs using HP OnGuard siRNA design, which incorporates neural-network technology and a proprietary homology analysis method. Also available are subsets targeting 426 GPCR genes, 738 kinase genes, or 198 phosphatase genes, Qiagen said.

HP OnGuard siRNA design uses an artificial neural network to select highly potent siRNAs and stringent homology analysis to ensure specificity. Additional features include design of siRNAs to target the most up-to-date sequences from the National Center for Biotechnology Information, 3' UTR/seed region analysis, SNP avoidance, and interferon motif avoidance, according to Qiagen.

 

siRNA design is reinforced using results from Qiagen’s validation project in which thousands of siRNAs have been tested for effectiveness by RT-PCR. In addition, data from Affymetrix GeneChip analysis is used to minimize the potential for off-target effects.

Rat druggable genome siRNAs are provided as individual siRNAs or pools. Either two or four individual siRNAs can be ordered for each gene at 0.25 nmol or 1 nmol scales allowing independent confirmation of phenotypes with multiple siRNAs, Qiagen said. Alternatively, pools of two or four siRNAs can be ordered at a total of 0.5 nmol or 1 nmol respectively.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.